CGEM Cullinan Oncology Inc

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference, being held in New York on February 5 and 6, 2025.

The fireside chat is scheduled for Wednesday, February 5, 2025, at 9:30 a.m. ET. A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at .

About Cullinan Therapeutics

 (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at , and follow us on  and .

Contacts:

Investor Relations

Nick Smith

+1 401.241.3516

Media

Rose Weldon

+1 215.801.7644



EN
30/01/2025

Underlying

CGEMCullinan Oncology Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cullinan Oncology Inc

Ritika Das ... (+2)
  • Ritika Das
  • Robert Driscoll
CGEM CULLINAN ONCOLOGY INC
05/08/25 May 8, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Provides Corporate Update and Reports First Quar...

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical com...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 ...

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States CLN-978 is the first and only development-stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases Sjögren’s disease represents the third indication under development for CLN-978, and is a disease with high unmet need and no currently approved therapies CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targe...

April 29, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 ...

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 study of zipalertinib in non-small ce...

April 23, 2025 1 EN
 PRESS RELEASE
Free
CGEM Cullinan Oncolo...

Cullinan Therapeutics Receives Approval from European Medicines Agency...

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythematosus CAMBRIDGE, Mass., April 16, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic t...

April 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch